The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Solov'eva É.Iu.

Kafedra nevrologii FUV GOU VPO RGMU, Moskva

Karneev A.N.

Chekanov A.V.

Baranova O.A.

Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova;
Nauchno-issledovatel'skiĭ institut fiziko-khimicheskoĭ meditsiny FMBA Rossii, laboratoriia fiziko-khimicheskikh metodov issledovaniia i analiza, Moskva

Choi I.V.

Pirogov Russian National Research Medical University, Moscow, Russia

Complex application 2-ethyl-6-methyl-3-hydroxypyridine-succinate and vinpocetine in cerebrovascular disorder

Authors:

Solov'eva É.Iu., Karneev A.N., Chekanov A.V., Baranova O.A., Choi I.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(5): 103‑108

DOI: 10.17116/jnevro201711751103-108

Read: 4661 times

Download PDF (RU)
Contact the author
Table of contents

COMPLEX APPLICATION 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE-SUCCINATE AND VINPOCETINE IN CEREBROVASCULAR DISORDER.
COMPLEX APPLICATION 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE-SUCCINATE AND VINPOCETINE IN CEREBROVASCULAR DISORDER.

To cite this article:

Solov'eva ÉIu, Karneev AN, Chekanov AV, Baranova OA, Choi IV. Complex application 2-ethyl-6-methyl-3-hydroxypyridine-succinate and vinpocetine in cerebrovascular disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(5):103‑108. (In Russ.)
https://doi.org/10.17116/jnevro201711751103-108

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Neurocytoprotection adva­nces in repe­rfusion therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):75-88
Effect of pro-inflammatory cyto­kines TNF-a and IL-1b on endo­thelial cells. Russian Cardiology Bulletin. 2024;(4-2):121-127
Histopathological characteristics of vascular anomalies of the maxi­llofacial region in young children. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(4-2):16-23
Pulmonary distress syndrome in urgent surgery: A concept, pathogenesis, and fundamentals of treatment. Piro­gov Russian Journal of Surgery. 2025;(2):77-85
Giant popliteal artery aneurysm. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):115-119
The level of hypo­xia-induced factor-1a and asso­ciated mole­cules in preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):5-10
Neuroprotective therapy of glaucoma. Russian Annals of Ophthalmology. 2025;(1):83-90
Asse­ssment of olfa­ctory level in acute sinu­sitis. Russian Rhinology. 2025;(1):6-11
Pote­ntial for the use of nutraceuticals for hype­rlipidemia correction. Russian Journal of Preventive Medi­cine. 2025;(3):40-45
Stru­ctural and functional tissue response to implants in patients with recu­rrent abdo­minal wall hernias in long-term period. Piro­gov Russian Journal of Surgery. 2025;(4):39-45
Abstract:

Developing brain ischemia due to cerebral vascularization leads to disruption of brain metabolism. Chronic cerebral hypoperfusion leads to irreversible brain damage and plays an important role in the development of some types of dementia. Early use of antioxidants such as ethyl ether apovincamine acid (vinpocetine) and 2-ethyl-6-methyl-3-hydroxypyridine-succinate in the treatment of this pathology is seen as a real pathogenetically based method of correction of cerebral metabolism with cerebral vascular disorders, demonstrating the increase in cerebral blood flow and also neuroprotective effects. Clinical studies and studies on biological models show that the main mechanisms of action of vinpocetine and 2-ethyl-6-methyl-3-hydroxypyridine-succinate, although have a similar focus, but implementing neuroprotective and nootropic effects via various links in the pathogenesis of ischemic brain damage.

Keywords:

endothelium
platelets
vascular oxidation
inflammation
hemostasis
neuroprotection
Vinpocetine
2-ethyl-6-methyl-3-hydroxypyridine-succinate
ischemia
atherosclerosis

Authors:

Solov'eva É.Iu.

Kafedra nevrologii FUV GOU VPO RGMU, Moskva

Karneev A.N.

Chekanov A.V.

Baranova O.A.

Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova;
Nauchno-issledovatel'skiĭ institut fiziko-khimicheskoĭ meditsiny FMBA Rossii, laboratoriia fiziko-khimicheskikh metodov issledovaniia i analiza, Moskva

Choi I.V.

Pirogov Russian National Research Medical University, Moscow, Russia

Close metadata

References:

  1. WHO. The Top 10 Causes of Death. Accessed on 14.11.16. Available online: http://www.who.int/mediacentre/factsheets/
  2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095-2128. doi:10.1016/S0140-6736(12)61728-0
  3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS. Heart disease and stroke statistics — 2013 update: A report from the american heart association. Circulation. 2013;127:6-245. doi:10.1161/CIR.0b013e31828124ad
  4. Adams HPJr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24:35-41.
  5. Ross R. Atherosclerosis — An inflammatory disease. N Engl J Med. 1999;340:115-126.
  6. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874. doi:10.1038/nature01323
  7. Hansson GK. Inflammation and immune response in atherosclerosis. Curr Atheroscler Rep. 1999;1:150-155.
  8. Candelario-Jalil E. Injury and repair mechanisms in ischemic stroke: Considerations for the development of novel neurotherapeutics. Curr Opin Investig Drugs. 2009;10:644-654.
  9. Macrez R, Ali C, Toutirais O, le Mauff B, Defer G, Dirnagl U, Vivien D. Stroke and the immune system: From pathophysiology to new therapeutic strategies. Lancet Neurol. 2011;10:471-480. doi:10.1016/S1474-4422(11)70066-7
  10. Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, Planas A, Rothwell N, Schwaninger M, Schwab ME. Improving outcome after stroke: Overcoming the translational roadblock. Cerebrovasc Dis. 2008;25:268-278.
  11. Iadecola C, Anrather J. The immunology of stroke: From mechanisms to translation. Nat Med. 2011;17:796-808. doi:10.1038/nm.2399
  12. Murray KN, Buggey HF, Denes A, Allan SM. Systemic immune activation shapes stroke outcome. Mol Cell Neurosci. 2013;53:14-25. doi:10.1016/j.mcn.2012.09.004
  13. Dabek J, Kulach A, Gasior Z. Nuclear factor κ-light-chain-enhancer of activated b cells (NF-κB): A new potential therapeutic target in atherosclerosis? Pharmacol Rep. 2010;62:778-783.
  14. Bereczki D, Fekete I. A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur J Clin Pharmacol. 1999;55:349-352.
  15. Shimizu Y, Saitoh K, Nakayama M. Agranulocytosis induced by vinpocetine. Medicine Online [serial online]. Accessed on 14.11.16. Available at:http://www.priory.com/med/vinpocetine.htm
  16. Rischke R, Krieglstein J. Effects of vinpocetine on local cerebral blood flow and glucose utilization seven days after forebrain ischemia in the rat. Pharmacology. 1990;41:153-160.
  17. Bonoczk P, Gulyas B, Adam-Vizi V, Nemes A, Karpati E, Kiss B, Kapas M. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull. 2000;53:245-254.
  18. Rischke R, Krieglstein J. Effects of vinpocetine on local cerebral blood flow and glucose utilization seven days after forebrain ischemia in the rat. Pharmacology. 1990;41:153-160.
  19. Beavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
  20. Truss MC, Uckert S, Stief CG, Forssmann WG, Jonas U. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res. 1996;24:129-134.
  21. Lakics V, Sebestyén MG, Erdö SL. Vinpocetine is a highly potent neuroprotectant against veratridine-induced cell death in primary cultures of rat cerebral cortex. Neurosci Lett. 1995;185:127-130.
  22. Zhao YY, Yu JZ, Li QY, Ma CG, Lu CZ, Xiao BG. Tspo-specific ligand vinpocetine exerts a neuroprotective effect by suppressing microglial inflammation. Neuron Glia Biol. 2011;7:187-197. doi:10.1017/S1740925X12000129
  23. Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk B., Li JD, Yan C. Vinpocetine inhibits NF-κB-dependent inflammation via an ikk-dependent but pde-independent mechanism. Proc Natl Acad Sci USA. 2010;10:9795-9800. doi:10.1073/pnas.0914414107
  24. Torres KJ, Gottle P, Kremer D, Rivera JF, Aguirre-Cruz L, Corona T, Hartung HP, Kury P. Vinpocetine inhibits oligodendroglial precursor cell differentiation. Cell Physiol Biochem. 2012;30:711-722. doi:10.1159/000341451
  25. Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan C. Vinpocetine inhibits NF-κB-dependent inflammation via an ikk-dependent but pde-independent mechanism. Proc Natl Acad Sci USA. 2010;107:9795-9800. doi:10.1073/pnas.0914414107
  26. Zhuang J, Peng W, Li H, Lu Y, Wang K, Fan F, Li S, Xu Y. Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by AKT/NF-κB dependent mechanisms in apoe-/-mice. PLoS One. 2013;8:82509. doi:10.1371/journal.pone.0082509
  27. Cai Y, Knight WE, Guo S, Li JD, Knight PA, Yan C. Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration. Pharmacol Exp Ther J. 2012;343:479-488. doi:10.1124/jpet.112.195446
  28. Ruiz-Miyazawa K, Pinho-Ribeiro FA, Zarpelon AC, Staurengo-Ferrari L, Silva RL, Alves-Filho JC, Cunha ThM, Cunha FQ, Casagrande R, Verri WAJr. Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-jB. Chemico-Biological Interactions. 2015;237:9-17. doi:10.1016/j.cbi.2015.05.007
  29. Voronina TA. Mexidol: range of pharmacological effects. Zhurnal Nevrologii i psikhiatrii im. S.S. Korsakova. 2012;12,86-90. (In Russ.).
  30. Voronina TA. Nootropic drugs in Alzheimer disease treatment. New Pharmacological Strategies. In: Alzheimer disease:therapeutic strategies., eds Boston: Birkhauser; 1994.
  31. Shulkin AV. Influence of a mexidol on development of a phenomenon of an exitotoksichnost of neurons of in vitro. Zhurnal Nevrologii i psikhiatrii im. S.S. Korsakova. 2012;2(2):35-39. (In Russ.).
  32. Voronina TA, Smirnov LD, Goryaynova II. Mekhanizm deistviya i obosnovanie primeneniya preparata meksidol v nevrologii: metodicheskie rekomendatsii. M.: Inctitut biokhimicheskoi fiziki, NII farmakologii RAMN; 2002. (In Russ.).
  33. Voronina TA. Antioxidant mtxidol. Main neuropsychotropic effects and mechanism of action. Psikhofarmakologiya i biologicheskaya narkologiya. 2001;1(1):2-12. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.